search
Back to results

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (LCN RESCU)

Primary Purpose

Cirrhosis, Cirrhosis, Liver, Cirrhosis Early

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Rosuvastatin
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cirrhosis focused on measuring Cirrhosis, Liver, Nonalcoholic Fatty Liver Disease, NASH, Nonalcoholic steatohepatitis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18-75 years Cirrhosis due to nonalcoholic steatohepatitis, alcohol-associated liver disease, or chronic viral hepatitis (treated hepatitis B virus or hepatitis C virus), or cryptogenic cirrhosis Clinical diagnosis of cirrhosis as defined investigator confirmation and the following: At least one liver biopsy within 5 years prior to consent showing either: Metavir stage 4 fibrosis; Ishak Stage 5-6 fibrosis, OR At least 2 of the following: i. Evidence on imaging: Nodular liver with either splenomegaly or recanalized umbilical vein within the past 48 weeks ii. Liver stiffness: vibration-controlled transient elastography within 48 weeks prior to consent or during Screening ≥12.5 kilopascal or magnetic resonance elastography within 48 weeks prior to consent or during Screening ≥5 kilopascal iii. Evidence of varices demonstrated on imaging or endoscopy within 3 years prior to consent or during Screening iv. Either: Fibrosis-4>2.67 or platelets <150/mL within 6 months prior to consent or during Screening Two measures of vibration-controlled transient elastography: one at screening and one at the randomization study visit, meeting the following criteria: The first measure must be ≥ 12.5 kilopascal. The two measures must be at least 1 day apart and no more than 60 days apart from one another. The mean of two measurements must be ≥ 12.5 kilopascal. Compensated defined by: Absence of ascites/hydrothorax, hepatic encephalopathy or variceal bleeding currently or in the last 48 weeks, as determined clinically by investigator. If prior history of decompensation, must be without current symptoms of decompensation and no longer requiring treatment of complications for the last 48 weeks, including the use of diuretics for the treatment of ascites, and/or rifaximin or lactulose for the treatment of hepatic encephalopathy. Use of non-selective beta blockers will be allowed. Child-Pugh score <8 Provision of written informed consent. Exclusion Criteria: Currently on a statin or any statin exposure within 48 weeks prior to consent. Known indication for statin therapy, defined as: Prior peripheral vascular, cardiovascular or cerebrovascular event for which statins are indicated for secondary prevention, OR Documented familial hypercholesterolemia, heterozygous familial hypercholesterolemia, OR Fasting LDL-C ≥ 190 mg/dL 4. Myocardial infarction, Unstable angina, transient ischemic events, or stroke within 24 weeks of screening. 3. Alcohol Use Disorder Identification Test (AUDIT) score of ≥8. 4. Patients with limitations in attending study visits. 5. Prisoners. 6. Known prior or current hepatocellular carcinoma (HCC) or cholangiocarcinoma. 7. Known transjugular intrahepatic portosystemic shunt (TIPS), balloon retrograde transvenous obliteration (BRTO) or porto-systemic shunt surgery regardless of time of occurrence. 8. Current (in past 24 weeks prior to consenting) use of medications known to cause hepatic fibrogenesis or confound endpoint assessment, defined as: amiodarone methotrexate warfarin 9. Current (in past 24 weeks prior to consenting) use of medications which may increase risk for rosuvastatin-related myositis or drug-induced liver injury, defined as: a. fenofibrate b. erythromycin c. gemfibrozil d. niacin (500 mg or more) e. HIV protease inhibitors (darunivar, indinavir, nelfinavir, amprenavir) in patients of East Asian descent f. colchicine g. cyclosporin 10. Presence of portal or hepatic vein thrombosis 11. Receiving an elemental diet or parenteral nutrition 12. Chronic pancreatitis or pancreatic insufficiency 13. Etiology of cirrhosis other than alcohol-associated liver disease, NAFLD, viral hepatitis or cryptogenic (including immune-mediated such as autoimmune hepatitis, primary sclerosing cholangitis and primary biliary cholangitis, cardiac cirrhosis or Fontan-associated liver disease, alpha-1-anti-trypsin, Wilson's disease, etc) 14. Conditions which may confound study outcome: a. Unstable or active inflammatory bowel disease b. Active infection c. Any malignant disease (other than squamous or basal cell carcinoma of the skin) within previous 5 years d. Prior solid organ or hematopoietic cell transplant e. Bariatric surgery in the last 24 weeks prior to consent or planned bariatric surgery within the next 96 weeks f. Current liver-unrelated end-stage organ failures such as end-stage renal disease on dialysis, stage 3-4 congestive heart failure (CHF), current chronic obstructive pulmonary disease (COPD) on home oxygen. 15. Known current medical or psychiatric conditions which, in the opinion of the investigator, would make the participant unsuitable for the study for safety reasons or interfere with or prevent adherence to the protocol. 16. The following laboratory abnormalities within 90 days of screening: Absolute neutrophil count <1.0 x 109 / L Hemoglobin <10 g/dL Albumin <3.0 g/dL Prolonged international normalized ratio (INR) >1.5 Total bilirubin ≥ 2.0 mg/dl (unless due to Gilbert's syndrome or hemolysis as denoted by normal direct bilirubin fraction) Uncontrolled diabetes (HbA1c ≥ 9.0%) within past 24 weeks 17. Kidney function abnormalities including: a. Dialysis b. Baseline epidermal growth factor receptor < 30 cc/min with chronic kidney disease-Epi equation c. Known nephrotic proteinuria, defined as 3g or greater of protein in 24-hour urine collection 18. Recent (within 48 weeks) or present hepatic decompensation with ascites/hydrothorax, hepatic encephalopathy or variceal bleeding 19. Untreated chronic hepatitis B or C infection Hepatitis C virus eligible for enrollment if hepatitis C virus RNA negative and after sustained virologic response at 24 weeks Hepatitis B virus eligible if Hepatitis B virus DNA <100 IU/mL and on treatment 20. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 200 U/L within the past 24 weeks 21. Documented history of intolerance to statins 22. Serious co-morbid medical disease which in the investigator's opinion renders a life-expectancy less than 96 weeks 23. Active illicit substance abuse, including inhaled or injected drugs, in the 48 weeks prior to screening 24. Pregnancy, planned pregnancy or breast-feeding 25. Current participation in active medication treatment trials (within 24 weeks prior to randomization) or planned participation in active medication treatment trials simultaneous to participation in present trial. 26. Significant existing muscle pain or tenderness as determined by a site physician. 27. Failure or inability to provide informed consent.

Sites / Locations

  • University of California San Diego NAFLD Research Center
  • Keck Medical Center of USC
  • LAC + USC Medical Center
  • UCSF/Zuckerberg San Francisco General Hospital and Trauma Center
  • UCSF Medical Center
  • University of Miami Health System
  • University of Michigan
  • Mayo Clinic
  • New York Presbyterian/Weill Cornell
  • Columbia University Iriving School of Medicine
  • Duke Liver Center
  • Cleveland ClinicRecruiting
  • Virginia Commonwealth University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Active

Placebo

Arm Description

Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry).

Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks placebo.

Outcomes

Primary Outcome Measures

Mean change in liver stiffness
Mean change in liver stiffness as measured in kilopascal with Vibration-Controlled Transient Elastography between study entry and week 96. Range: 2 to 75 kilopascal. Higher stiffness indicates increased disease progression

Secondary Outcome Measures

Time to disease progression
Time to disease progression defined as time to development of decompensation event (ascites, hepatic encephalopathy, variceal bleed) or hepatocellular carcinoma. Analyzed as time-to-event; binary if low counts.
All-cause mortality
All-cause mortality: time-to-event, binary if low counts
Time to development of ascites
Ascites: time-to-event, binary if low counts
Time to development of overt hepatic encephalopathy
Time to development of overt hepatic encephalopathy: time-to-event, binary if low counts
Time to development of variceal bleed
Variceal bleed: time-to-event, binary if low counts
Time to development of hepatocellular carcinoma
Hepatocellular carcinoma: time-to-event, binary if low counts
Change in Child-Turcotte-Pugh score
Ordinal score from 5 to 15; higher score indicates further disease progression
Change in Model for End Stage Liver Disease - Sodium (MELD-Na)
Unitless; Range: 6-40; higher score indicates further disease progression
Change in spleen stiffness as measured by Vibration-Controlled Transient Elastography (VCTE)
Units: kilopascal; Range: 5 to 100 kilopascal; higher stiffness indicates increased disease progression
Change in liver stiffness via Magnetic Resonance Elastography
Units: kilopascal; Range: 0 to 20; higher stiffness indicates increased disease progression
Change in Enhanced Liver Fibrosis test
Unitless; Range: 5 to 11; Higher score is worse
Change in Fibrosis-4
Unitless; Range: 0 to 10; higher score indicates more stiffness
Time to new onset diabetes
New onset diabetes: time-to-event, binary if low counts
Time to cardiovascular events
Cardiovascular events: time-to-event, binary if low counts
Change in patient-reported quality of life scores
Patient Reported Outcomes Measurement Information System (29-item version) Global Health T-Score: Population centered at 50 points, standard deviation of 10 (higher score signifies "better" health)
Rate of adverse events
Count
Rate of serious adverse events
Count
Rate of adverse events of special interest
Rate of adverse events of special interest (myopathy, drug-induced liver injury, cardiovascular events, cancer other than hepatocellular carcinoma, new onset diabetes as separate outcomes): Count

Full Information

First Posted
March 24, 2023
Last Updated
October 18, 2023
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
search

1. Study Identification

Unique Protocol Identification Number
NCT05832229
Brief Title
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Acronym
LCN RESCU
Official Title
Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 11, 2023 (Actual)
Primary Completion Date
November 1, 2026 (Anticipated)
Study Completion Date
November 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Detailed Description
This study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial, of 20mg (or 10mg for participants of East Asian ancestry) of rosuvastatin by mouth, once daily. Participants will be randomized (1:1) to either once daily placebo or once daily rosuvastatin. Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry) or matching placebo. The total duration of the study will be 96 weeks in the assigned treatment arm plus the 4-week lead-in period. The primary outcome will be the mean change in liver stiffness from the baseline measurement to the end of study liver stiffness, as measured by ultrasound-based vibration-controlled transient elastography (VCTE). There are 10 participating clinical centers, and we anticipate a total of 256 patients will be recruited for the initial lead-in as we estimate 20% of participants may dropout after the lead-in (256 x 0.8 = 204 for randomization into the study drug treatment phase).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
Keywords
Cirrhosis, Liver, Nonalcoholic Fatty Liver Disease, NASH, Nonalcoholic steatohepatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
This study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial, of 20mg (or 10mg for participants of East Asian ancestry) of rosuvastatin by mouth, once daily. Participants will be randomized (1:1) to either once daily placebo or once daily rosuvastatin.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The drug manufacturer and bottler will be unblinded, as will a few members of the Scientific and Data Coordinating Center. All other study team members will remain blinded.
Allocation
Randomized
Enrollment
256 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active
Arm Type
Experimental
Arm Description
Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks placebo.
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Rosuvastatin 20 mg, Rosuvastatin 10 mg
Intervention Description
Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry) or matching placebo.
Primary Outcome Measure Information:
Title
Mean change in liver stiffness
Description
Mean change in liver stiffness as measured in kilopascal with Vibration-Controlled Transient Elastography between study entry and week 96. Range: 2 to 75 kilopascal. Higher stiffness indicates increased disease progression
Time Frame
96 weeks
Secondary Outcome Measure Information:
Title
Time to disease progression
Description
Time to disease progression defined as time to development of decompensation event (ascites, hepatic encephalopathy, variceal bleed) or hepatocellular carcinoma. Analyzed as time-to-event; binary if low counts.
Time Frame
96 weeks
Title
All-cause mortality
Description
All-cause mortality: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Time to development of ascites
Description
Ascites: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Time to development of overt hepatic encephalopathy
Description
Time to development of overt hepatic encephalopathy: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Time to development of variceal bleed
Description
Variceal bleed: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Time to development of hepatocellular carcinoma
Description
Hepatocellular carcinoma: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Change in Child-Turcotte-Pugh score
Description
Ordinal score from 5 to 15; higher score indicates further disease progression
Time Frame
96 weeks
Title
Change in Model for End Stage Liver Disease - Sodium (MELD-Na)
Description
Unitless; Range: 6-40; higher score indicates further disease progression
Time Frame
96 weeks
Title
Change in spleen stiffness as measured by Vibration-Controlled Transient Elastography (VCTE)
Description
Units: kilopascal; Range: 5 to 100 kilopascal; higher stiffness indicates increased disease progression
Time Frame
96 weeks
Title
Change in liver stiffness via Magnetic Resonance Elastography
Description
Units: kilopascal; Range: 0 to 20; higher stiffness indicates increased disease progression
Time Frame
96 weeks
Title
Change in Enhanced Liver Fibrosis test
Description
Unitless; Range: 5 to 11; Higher score is worse
Time Frame
96 weeks
Title
Change in Fibrosis-4
Description
Unitless; Range: 0 to 10; higher score indicates more stiffness
Time Frame
96 weeks
Title
Time to new onset diabetes
Description
New onset diabetes: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Time to cardiovascular events
Description
Cardiovascular events: time-to-event, binary if low counts
Time Frame
96 weeks
Title
Change in patient-reported quality of life scores
Description
Patient Reported Outcomes Measurement Information System (29-item version) Global Health T-Score: Population centered at 50 points, standard deviation of 10 (higher score signifies "better" health)
Time Frame
96 weeks
Title
Rate of adverse events
Description
Count
Time Frame
96 weeks
Title
Rate of serious adverse events
Description
Count
Time Frame
96 weeks
Title
Rate of adverse events of special interest
Description
Rate of adverse events of special interest (myopathy, drug-induced liver injury, cardiovascular events, cancer other than hepatocellular carcinoma, new onset diabetes as separate outcomes): Count
Time Frame
96 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-75 years Cirrhosis due to nonalcoholic steatohepatitis, alcohol-associated liver disease, or chronic viral hepatitis (treated hepatitis B virus or hepatitis C virus), or cryptogenic cirrhosis Clinical diagnosis of cirrhosis as defined investigator confirmation and the following: At least one liver biopsy within 5 years prior to consent showing either: Metavir stage 4 fibrosis; Ishak Stage 5-6 fibrosis, OR At least 2 of the following: i. Evidence on imaging: Nodular liver with either splenomegaly or recanalized umbilical vein within the past 48 weeks ii. Liver stiffness: vibration-controlled transient elastography within 48 weeks prior to consent or during Screening ≥12.5 kilopascal or magnetic resonance elastography within 48 weeks prior to consent or during Screening ≥5 kilopascal iii. Evidence of varices demonstrated on imaging or endoscopy within 3 years prior to consent or during Screening iv. Either: Fibrosis-4>2.67 or platelets <150/mL within 6 months prior to consent or during Screening Two measures of vibration-controlled transient elastography: one at screening and one at the randomization study visit, meeting the following criteria: The first measure must be ≥ 12.5 kilopascal. The two measures must be at least 1 day apart and no more than 60 days apart from one another. The mean of two measurements must be ≥ 12.5 kilopascal. Compensated defined by: Absence of ascites/hydrothorax, hepatic encephalopathy or variceal bleeding currently or in the last 48 weeks, as determined clinically by investigator. If prior history of decompensation, must be without current symptoms of decompensation and no longer requiring treatment of complications for the last 48 weeks, including the use of diuretics for the treatment of ascites, and/or rifaximin or lactulose for the treatment of hepatic encephalopathy. Use of non-selective beta blockers will be allowed. Child-Pugh score <8 Provision of written informed consent. Exclusion Criteria: Currently on a statin or any statin exposure within 48 weeks prior to consent. Known indication for statin therapy, defined as: Prior peripheral vascular, cardiovascular or cerebrovascular event for which statins are indicated for secondary prevention, OR Documented familial hypercholesterolemia, heterozygous familial hypercholesterolemia, OR Fasting LDL-C ≥ 190 mg/dL 4. Myocardial infarction, Unstable angina, transient ischemic events, or stroke within 24 weeks of screening. 3. Alcohol Use Disorder Identification Test (AUDIT) score of ≥8. 4. Patients with limitations in attending study visits. 5. Prisoners. 6. Known prior or current hepatocellular carcinoma (HCC) or cholangiocarcinoma. 7. Known transjugular intrahepatic portosystemic shunt (TIPS), balloon retrograde transvenous obliteration (BRTO) or porto-systemic shunt surgery regardless of time of occurrence. 8. Current (in past 24 weeks prior to consenting) use of medications known to cause hepatic fibrogenesis or confound endpoint assessment, defined as: amiodarone methotrexate warfarin 9. Current (in past 24 weeks prior to consenting) use of medications which may increase risk for rosuvastatin-related myositis or drug-induced liver injury, defined as: a. fenofibrate b. erythromycin c. gemfibrozil d. niacin (500 mg or more) e. HIV protease inhibitors (darunivar, indinavir, nelfinavir, amprenavir) in patients of East Asian descent f. colchicine g. cyclosporin 10. Presence of portal or hepatic vein thrombosis 11. Receiving an elemental diet or parenteral nutrition 12. Chronic pancreatitis or pancreatic insufficiency 13. Etiology of cirrhosis other than alcohol-associated liver disease, NAFLD, viral hepatitis or cryptogenic (including immune-mediated such as autoimmune hepatitis, primary sclerosing cholangitis and primary biliary cholangitis, cardiac cirrhosis or Fontan-associated liver disease, alpha-1-anti-trypsin, Wilson's disease, etc) 14. Conditions which may confound study outcome: a. Unstable or active inflammatory bowel disease b. Active infection c. Any malignant disease (other than squamous or basal cell carcinoma of the skin) within previous 5 years d. Prior solid organ or hematopoietic cell transplant e. Bariatric surgery in the last 24 weeks prior to consent or planned bariatric surgery within the next 96 weeks f. Current liver-unrelated end-stage organ failures such as end-stage renal disease on dialysis, stage 3-4 congestive heart failure (CHF), current chronic obstructive pulmonary disease (COPD) on home oxygen. 15. Known current medical or psychiatric conditions which, in the opinion of the investigator, would make the participant unsuitable for the study for safety reasons or interfere with or prevent adherence to the protocol. 16. The following laboratory abnormalities within 90 days of screening: Absolute neutrophil count <1.0 x 109 / L Hemoglobin <10 g/dL Albumin <3.0 g/dL Prolonged international normalized ratio (INR) >1.5 Total bilirubin ≥ 2.0 mg/dl (unless due to Gilbert's syndrome or hemolysis as denoted by normal direct bilirubin fraction) Uncontrolled diabetes (HbA1c ≥ 9.0%) within past 24 weeks 17. Kidney function abnormalities including: a. Dialysis b. Baseline epidermal growth factor receptor < 30 cc/min with chronic kidney disease-Epi equation c. Known nephrotic proteinuria, defined as 3g or greater of protein in 24-hour urine collection 18. Recent (within 48 weeks) or present hepatic decompensation with ascites/hydrothorax, hepatic encephalopathy or variceal bleeding 19. Untreated chronic hepatitis B or C infection Hepatitis C virus eligible for enrollment if hepatitis C virus RNA negative and after sustained virologic response at 24 weeks Hepatitis B virus eligible if Hepatitis B virus DNA <100 IU/mL and on treatment 20. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 200 U/L within the past 24 weeks 21. Documented history of intolerance to statins 22. Serious co-morbid medical disease which in the investigator's opinion renders a life-expectancy less than 96 weeks 23. Active illicit substance abuse, including inhaled or injected drugs, in the 48 weeks prior to screening 24. Pregnancy, planned pregnancy or breast-feeding 25. Current participation in active medication treatment trials (within 24 weeks prior to randomization) or planned participation in active medication treatment trials simultaneous to participation in present trial. 26. Significant existing muscle pain or tenderness as determined by a site physician. 27. Failure or inability to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mary Beth Tull
Phone
312-503-4746
Email
lcn@northwestern.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jody Ciolino
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Diego NAFLD Research Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92035
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rohit Loomba
Email
roloomba@health.ucsd.edu
Facility Name
Keck Medical Center of USC
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Norah Terrault
Email
norah.terrault@med.usc.edu
Facility Name
LAC + USC Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Norah Terrault
Email
norah.terrault@med.usc.edu
Facility Name
UCSF/Zuckerberg San Francisco General Hospital and Trauma Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mandana Khalili
Email
Mandana.Khalili@ucsf.edu
Facility Name
UCSF Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bilal Hameed
Email
bilal.hameed@ucsf.edu
Facility Name
University of Miami Health System
City
Miami
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Goldberg
Email
dsgoldberg@med.miami.edu
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elliot Tapper
Email
etapper@med.umich.edu
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55901
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vijay Shah
Email
Shah.Vijay@mayo.edu
Facility Name
New York Presbyterian/Weill Cornell
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Brown
Email
rsb2005@med.cornell.edu
Facility Name
Columbia University Iriving School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10031
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Verna
Email
ev77@cumc.columbia.edu
Facility Name
Duke Liver Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Mae Diehl
Email
diehl004@mc.duke.edu
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44192
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Srinivasan Dasarathy
Email
DASARAS@ccf.org
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arun Sanyal
Email
arun.sanyal@vcuhealth.org

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Dataset with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository.
Links:
URL
http://www.lcnstudy.org
Description
Information about the study

Learn more about this trial

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

We'll reach out to this number within 24 hrs